ELRIG Drug Discovery 2026 has ended. This guide stays up as the record of who was there. Next: ELRIG DD 2027, Oct 19–20, 2027 in Liverpool
Biotech companies at ELRIG Drug Discovery 2026
Oct 14–15, 2026 London, UK ~3k attendees Website
27 biotech companies are at ELRIG Drug Discovery 2026 — 20 presentations on the program and 8 with a booth in the exhibit hall. Most represented: Ignota Labs (2 on the program), Creasallis (1 on the program), Amphista Therapeutics (1 on the program). 11 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–19 of 27 organizations
| Organization | ELRIG Drug Discovery 2026 Attendance |
|---|---|
Ignota Labs Cambridge, UK | |
AI company rescuing failed or shelved drug candidates by solving safety problems and creating new chemistry and IP. | Talk Thu Oct 15 12:40pm–1:10pm Panel Thu Oct 15 3:30pm–4:00pm |
Creasallis Cambridge, UK | |
Develops a modification that helps antibodies and conjugates penetrate deeper into solid tumours, alongside its own oncology antibody programs. | Talk Thu Oct 15 3:00pm–3:30pm Panel Thu Oct 15 3:30pm–4:00pm |
Develops small-molecule medicines based on targeted protein degradation. | Chair Thu Oct 15 10:50am–10:55am Track Chair - From multi-omics to clinical outcomes: Insights for drug development How much molecular data and how many participants early studies need, and which signals from large biological datasets can be trusted. |
Apollo Therapeutics Cambridge, UK | |
Biotech developing a portfolio of medicines built on academic science, with programmes in oncology and immunology. | Talk Wed Oct 14 2:40pm–3:10pm |
Artios Pharma Cambridge, UK | |
Develops DNA damage response medicines for cancer, including small molecules and payloads for antibody-drug conjugates. | Talk Wed Oct 14 4:30pm–5:00pm |
Develops pre|CISION peptide drug conjugates whose cytotoxic payloads are released when FAP cleaves them in the tumour microenvironment. | |
Bicycle Therapeutics Cambridge, UK | |
Develops medicines from bicyclic peptides, including toxin and radionuclide conjugates for solid tumours. | |
Develops antibody therapies for immune-driven disease, including an anti-S100A4 antibody for chronic inflammatory and fibrotic conditions. | |
Constructive Bio Cambridge, UK | |
Expands the genetic code to build proteins containing new-to-nature chemical building blocks for next-generation therapeutics. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
Women's health start-up studying menstrual-fluid-derived tissue and the extracellular matrix to find treatments for endometriosis. | Talk Thu Oct 15 11:55am–12:25pm |
AI company building digital twins of cells from multi-omics data to prioritise targets and support drug repositioning. | Talk Wed Oct 14 3:45pm–4:15pm |
ExpressionEdits Cambridge, UK | |
Adds introns to synthetic gene designs, guided by an AI engine, to raise expression of hard-to-make therapeutic proteins. | Talk Wed Oct 14 12:20pm–12:50pm |
Iksuda Therapeutics Newcastle, UK | |
Develops antibody-drug conjugates for hard-to-treat cancers, including a new protein-alkylating payload class. | Talk Wed Oct 14 2:00pm–2:30pm |
Isomorphic Labs London, UK | |
AI drug discovery company, spun out of Google DeepMind, building predictive models to design new medicines. | Chair Thu Oct 15 10:50am–10:55am Track Chair- Innovation Zone How early-stage life science companies raise money, carry discoveries toward market and build portfolios, and where such efforts commonly fail. |
Molecular Partners Zurich, Switzerland | |
Clinical-stage biotech developing DARPin protein therapeutics. | Talk Thu Oct 15 10:55am–11:25am |
Nxera Pharma Tokyo, Japan | |
Biopharma company, formerly Sosei Heptares, combining structure-based GPCR drug design with a commercial business in Japan. | Talk Wed Oct 14 11:20am–11:50am |
Precision immunology start-up aiming to detect, monitor and treat autoimmune and other immune-driven inflammatory conditions earlier. | Panel Thu Oct 15 9:30am–10:15am Keynote Panel - 20 Years of Discovery: Lessons from the Past, Blueprints for the Next 20 What two decades of change in drug discovery, from high-throughput screening to AI design, teach about building the next generation of medicines. |
Unnatural Products Santa Cruz, CA | |
Develops synthetic macrocyclic peptide drugs aiming for antibody-like potency and selectivity with oral delivery. | |
Developing restoration therapeutics that aim to restore healthy function in specific cell types, starting with neural and skin programmes. | Booth Exhibiting (no floor booth listed) Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Exhibiting in the Breakthrough Zone (start-ups and emerging companies) |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ELRIG Drug Discovery 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by ELRIG. Submit a correction